<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Dermatol</journal-id><journal-title-group><journal-title>BMC Dermatology</journal-title></journal-title-group><issn pub-type="epub">1471-5945</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27455955</article-id><article-id pub-id-type="pmc">4960797</article-id><article-id pub-id-type="publisher-id">48</article-id><article-id pub-id-type="doi">10.1186/s12895-016-0048-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50&#x000a0;mg twice weekly followed by etanercept 25&#x000a0;mg twice weekly, the combination of etanercept 25&#x000a0;mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Lee</surname><given-names>Joo-Heung</given-names></name><address><phone>82-2-3410-3542</phone><email>joosoo@skku.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Youn</surname><given-names>Jai-Il</given-names></name><address><email>jaiil@snu.ac.kr</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Tae-Yoon</given-names></name><address><email>tykimder@catholic.ac.kr</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Jee-Ho</given-names></name><address><email>hchoy@amc.seoul.kr</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Chul-Jong</given-names></name><address><email>cjpark777smp@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Choe</surname><given-names>Yong-Beom</given-names></name><address><email>cyb@kuh.ac.kr</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Hae-Jun</given-names></name><address><email>hjsongmd@gmail.com</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Nack-In</given-names></name><address><email>nikim@khmc.or.kr</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Kwang-Joong</given-names></name><address><email>kkj51818@hallym.or.kr</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jeung-Hoon</given-names></name><address><email>jhoon@cnu.ac.kr</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Yoo</surname><given-names>Hyun-Jeong</given-names></name><address><email>Hyun-Jeong.Yoo@pfizer.com</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><aff id="Aff1"><label>1</label>Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, Korea </aff><aff id="Aff2"><label>2</label>Department of Dermatology, National Medical Center, Seoul, Korea </aff><aff id="Aff3"><label>3</label>Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea </aff><aff id="Aff4"><label>4</label>Department of Dermatology, Asian Medical Center, University of Ulsan College of Medicine, Seoul, Korea </aff><aff id="Aff5"><label>5</label>Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea </aff><aff id="Aff6"><label>6</label>Department of Dermatology, College of Medicine, Korea University, Seoul, Korea </aff><aff id="Aff7"><label>7</label>Department of Dermatology, College of Medicine, Kyung Hee University, Seoul, Korea </aff><aff id="Aff8"><label>8</label>Department of Dermatology, Hallym University Sacred Heart Hospital, Seoul, Korea </aff><aff id="Aff9"><label>9</label>Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Korea </aff><aff id="Aff10"><label>10</label>Pfizer Pharmaceuticals Korea Limited, Seoul, Korea </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>16</volume><elocation-id>11</elocation-id><history><date date-type="received"><day>28</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>8</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Etanercept, a soluble tumor necrosis factor receptor, and acitretin have been shown to be effective in treating psoriasis. Acitretin is widely used in Korea. However, the combination of etanercept plus acitretin has not been evaluated among Korean patients with psoriasis. The objective of this study was to investigate the efficacy and safety of combination therapy with etanercept and acitretin in patients with moderate to severe plaque psoriasis.</p></sec><sec><title>Methods</title><p>Sixty patients with psoriasis were randomized to receive etanercept 50&#x000a0;mg twice weekly (BIW) for 12&#x000a0;weeks followed by etanercept 25&#x000a0;mg BIW for 12&#x000a0;weeks (ETN-ETN); etanercept 25&#x000a0;mg BIW plus acitretin 10&#x000a0;mg twice daily (BID) for 24&#x000a0;weeks (ETN-ACT); or acitretin 10&#x000a0;mg BID for 24&#x000a0;weeks (ACT). The primary efficacy measurement was the proportion of patients achieving 75&#x000a0;% improvement in Psoriasis Area and Severity Index (PASI 75) at week 24. Secondary end points included 50&#x000a0;% improvement in PASI (PASI 50) at week 24 and clear/almost-clear by Physician Global Assessment (PGA) at each visit through week 24.</p></sec><sec><title>Results</title><p>The proportions of patients achieving PASI 75, PASI 50, and PGA clear/almost-clear at week 24 in the ETN-ETN (52.4, 71.4, and 52.4&#x000a0;%, respectively) and ETN-ACT groups (57.9, 84.2, and 52.6&#x000a0;%, respectively) were higher than in the ACT group (22.2, 44.4, and 16.7&#x000a0;%, respectively). The incidence of adverse events was similar across all arms. This was an open-label study with a small number of patients.</p></sec><sec><title>Conclusion</title><p>In Korean patients with moderate to severe plaque psoriasis, etanercept alone or in combination with acitretin was more effective than acitretin. All treatments were well tolerated throughout the study.</p></sec><sec><title>Trial registration</title><p>This study was registered on July 7, 2009 at ClinicalTrials.gov, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00936065">NCT00936065</ext-link>.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Psoriasis</kwd><kwd>Etanercept</kwd><kwd>Acitretin</kwd><kwd>Combination therapy</kwd><kwd>Efficacy</kwd><kwd>Safety</kwd><kwd>Korean patients</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/http://dx.doi.org/10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Psoriasis is a chronic autoimmune condition that affects 1 to 3&#x000a0;% of the general population worldwide [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Psoriasis has been associated with an increased risk for arthritis [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], diabetes [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], cardiovascular disease [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], depression [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], and poor quality of life (QoL) [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Although there is as yet no cure [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>], there are several effective treatments available to manage the disease [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>In clinical trials, etanercept, a tumor necrosis factor-alpha (TNF&#x003b1;) inhibitor, has been shown to be effective in managing psoriasis including improvements in Psoriasis Area Severity Index (PASI) scores [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>], Physician&#x02019;s Global Assessment (PGA) [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], and QoL [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Acitretin, a systemic retinoid, is also effective for the management of psoriasis [<xref ref-type="bibr" rid="CR21">21</xref>]. Acitretin is frequently used in combination with other agents (e.g., phototherapy and vitamin D), since acitretin monotherapy is often only moderately effective [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. Since acitretin is not an immunosuppressive agent, combination treatment with etanercept may have a synergistic effect with a low risk of toxicity [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. This has been demonstrated in a pilot study in which the combination of acitretin and low-dose etanercept was as effective as high-dose etanercept, and both were significantly more effective than acitretin alone [<xref ref-type="bibr" rid="CR25">25</xref>]. The purpose of the current study was to evaluate combination therapy of etanercept plus acitretin among Korean patients with psoriasis.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Patients</title><p>This study was reviewed and approved by local Institutional Review Boards (<xref rid="Sec13" ref-type="sec">Appendix</xref>) and was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with Good Clinical Practice Guidelines. All patients provided signed informed consent.</p><p>Patients were eligible for study enrolment if they were at least 18&#x000a0;years of age and had active, clinically stable moderate to severe plaque psoriasis involving &#x02265;10&#x000a0;% body surface area (BSA) or PASI &#x02265;10. Exclusion criteria included evidence of skin conditions (e.g., eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis; any rheumatologic disease; prior exposure to biologic therapies, including etanercept, within 24&#x000a0;weeks of baseline visit; previous history of phototherapy or any systemic or topical therapy, including acitretin, for psoriasis within the previous 28&#x000a0;days before baseline visit; uncontrolled hypertension or diabetes mellitus; any severe hematologic, cardiovascular, renal, hepatic, or pulmonary disorders; known contraindication or hypersensitivity to etanercept or acitretin or their excipients; women who were pregnant, expecting to become pregnant, or breast-feeding during the study period; patients with any clinically relevant concurrent medical conditions such as active or chronic infections, including human immunodeficiency virus, hepatitis B virus and hepatitis C virus infections, and active or recent (within 2&#x000a0;years) tuberculosis; history of cancer (or carcinoma in situ) other than resected cutaneous basal cell or squamous cell carcinoma within the past 5&#x000a0;years before the screening visit; or patients who had received any investigational drug within 3&#x000a0;months of screening visit.</p></sec><sec id="Sec4"><title>Study design</title><p>In this multicenter, randomized, open-label trial, patients were randomly assigned to one of three treatment groups: (a) etanercept 50&#x000a0;mg twice weekly (BIW) for 12&#x000a0;weeks followed by etanercept 25&#x000a0;mg BIW for a further 12&#x000a0;weeks (ETN&#x02013;ETN); (b) etanercept 25&#x000a0;mg BIW and acitretin 10&#x000a0;mg twice daily (BID) for 24&#x000a0;weeks (ETN-ACT); (c) acitretin 10&#x000a0;mg BID for 24&#x000a0;weeks (ACT; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). This study was conducted in compliance with the ethical principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines and registered on ClinicalTrials.gov, identifier NCT00936065.<fig id="Fig1"><label>Fig. 1</label><caption><p>Study design. <italic>ACT</italic>, acitretin; <italic>BID</italic>, twice daily; <italic>BIW</italic>, twice weekly; <italic>ETN</italic>, etanercept</p></caption><graphic xlink:href="12895_2016_48_Fig1_HTML" id="MO1"/></fig></p><p>The primary endpoint was proportion of patients achieving &#x02265;75&#x000a0;% improvement from baseline in PASI score (PASI 75) at week 24. Secondary endpoints included the proportion of patients achieving either PASI 75 or PASI 50 (&#x02265;50&#x000a0;% improvement from baseline) at each visit through week 24, PGA status of &#x0201c;clear/almost-clear&#x0201d;, and change in percent of BSA involvement from baseline over time.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p>The sample size was calculated assuming 20 patients per group with a response rate of 35&#x02013;65&#x000a0;% which would yield a confidence interval below &#x0200b;&#x000b1; 21.9&#x000a0;%. Further assuming the response rate difference for primary efficacy endpoints is 20&#x000a0;% (i.e., 40 vs. 60&#x000a0;%), the 95&#x000a0;% confidence interval would be approximately &#x0200b;&#x000b1; 30&#x000a0;%.</p><p>Statistical analysis was performed using SAS software, version 9.13. Efficacy evaluation was performed on the modified intent-to-treat (mITT) and per protocol (PP) population sets. The mITT population included all randomly assigned patients who received at least one dose of test medication and had both baseline and on-therapy PASI evaluations. The PP population included those members of the mITT population who had no major protocol violations that could potentially alter the interpretation of the efficacy analysis.</p><p>For the outcomes at each visit, the proportions of responders and the 95&#x000a0;% confidence interval (CI) were determined and the differences between treatment groups were assessed using Fisher exact test or Chi-square test with multiple comparisons, if necessary. Kaplan-Meier estimations for time to first occurrence of each event were determined and the log-rank test was used for statistical testing. For these analyses, no imputation was applied and the patients who did not experience the event were censored at the time of last observation.</p><p>Basic descriptive statistics are presented for other measures and the statistical significance of the change from baseline within the treatment groups was assessed using the paired <italic>t</italic>-test or the Wilcoxon signed-rank test. Differences in change from baseline between the treatment groups were assessed using one-way analysis of variance (ANOVA) or the Kruskal-Wallis test.</p></sec></sec><sec id="Sec6"><title>Results</title><p>All results of this study have been posted on ClinicalTrials.gov, NCT00936065.</p><sec id="Sec7"><title>Patients</title><p>Of the 60 patients enrolled in this study and randomized to the three treatment arms, 45 completed the study (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). One patient withdrew from the study after randomization but before receiving any study medication. Reasons for study discontinuation included patient request (<italic>n</italic>&#x02009;=&#x02009;6), protocol violation (<italic>n</italic>&#x02009;=&#x02009;4), unsatisfactory response (<italic>n</italic>&#x02009;=&#x02009;2), adverse event (AE; <italic>n</italic>&#x02009;=&#x02009;2), and lost to follow-up (<italic>n</italic>&#x02009;=&#x02009;1). The baseline demographics were similar across all treatment arms (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Patient disposition. <italic>ACT</italic>, acitretin; <italic>ETN</italic>, etanercept; <italic>mITT</italic>, modified intent-to-treat population; <italic>PP</italic>, per-protocol population</p></caption><graphic xlink:href="12895_2016_48_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline demographics for the mITT population</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>ETN 50&#x000a0;mg&#x02013;ETN 25&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;21)</th><th>ETN 25&#x000a0;mg&#x02013;ACT 10&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;19)</th><th>ACT 10&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;18)</th><th>Total (<italic>N</italic>&#x02009;=&#x02009;58)</th></tr></thead><tbody><tr><td>Mean age, y (SD)</td><td>38.6 (9.5)</td><td>35.5 (8.8)</td><td>42.4 (12.0)</td><td>38.8 (10.3)</td></tr><tr><td>Mean height, cm (SD)</td><td>169.5 (9.3)</td><td>171.7 (5.5)</td><td>170.9 (6.8)</td><td>170.6 (7.4)</td></tr><tr><td>Mean weight, kg (SD)</td><td>74.1 (16.0)</td><td>74.0 (11.6)</td><td>74.2 (9.8)</td><td>74.1 (12.7)</td></tr><tr><td>Gender, n (%)</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Male</td><td>16 (76.2&#x000a0;%)</td><td>17 (89.5&#x000a0;%)</td><td>15 (83.3&#x000a0;%)</td><td>48 (82.8&#x000a0;%)</td></tr><tr><td>Cigarette status, n (%)</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Prior cigarette usage</td><td>5 (23.8&#x000a0;%)</td><td>5 (26.3&#x000a0;%)</td><td>3 (16.7&#x000a0;%)</td><td>13 (22.4&#x000a0;%)</td></tr><tr><td>&#x02003;Current cigarette usage</td><td>10 (47.6&#x000a0;%)</td><td>11 (57.9&#x000a0;%)</td><td>10 (55.6&#x000a0;%)</td><td>31 (53.5&#x000a0;%)</td></tr><tr><td>&#x02003;No</td><td>6 (28.6&#x000a0;%)</td><td>3 (15.8&#x000a0;%)</td><td>5 (27.8&#x000a0;%)</td><td>14 (24.1&#x000a0;%)</td></tr><tr><td>Alcohol status, n (%)</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Ex-drinker</td><td>2 (9.5&#x000a0;%)</td><td>2 (10.5&#x000a0;%)</td><td>2 (11.1&#x000a0;%)</td><td>6 (10.3&#x000a0;%)</td></tr><tr><td>&#x02003;Current-drinker</td><td>13 (61.9&#x000a0;%)</td><td>13 (68.4&#x000a0;%)</td><td>11 (61.1&#x000a0;%)</td><td>37 (63.8&#x000a0;%)</td></tr><tr><td>&#x02003;No</td><td>6 (28.6&#x000a0;%)</td><td>4 (21.1&#x000a0;%)</td><td>5 (27.8&#x000a0;%)</td><td>15 (25.9&#x000a0;%)</td></tr><tr><td>Prior therapies for psoriasis, n (%)</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Methotrexate</td><td>2 (9.5&#x000a0;%)</td><td>1 (5.3&#x000a0;%)</td><td>0</td><td>3 (5.2&#x000a0;%)</td></tr><tr><td>&#x02003;Cyclosporine</td><td>2 (9.5&#x000a0;%)</td><td>2 (10.5&#x000a0;%)</td><td>1 (5.6&#x000a0;%)</td><td>5 (8.6&#x000a0;%)</td></tr><tr><td>&#x02003;PUVA</td><td>0</td><td>3 (15.8&#x000a0;%)</td><td>0</td><td>3 (5.2&#x000a0;%)</td></tr><tr><td>&#x02003;Other<sup>a</sup>
</td><td>12 (57.1&#x000a0;%)</td><td>12 (63.2&#x000a0;%)</td><td>10 (55.6&#x000a0;%)</td><td>34 (58.6&#x000a0;%)</td></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviations</italic>: <italic>ACT</italic> acitretin, <italic>CS</italic> clinically significant, <italic>ETN</italic> etanercept, <italic>mITT</italic> modified intent-to-treat population, <italic>NCS</italic> not clinically significant, <italic>PUVA</italic> psoralen plus ultraviolet A radiation therapy, <italic>SD</italic> standard deviation</p><p>
<sup>a</sup>Includes systemic antimycobacterials, medication for treating alimentary tract and metabolism conditions, cardiovascular drugs, respiratory drugs, dermatologicals, and systemic hormonal preparations</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec8"><title>Efficacy</title><p>The proportion of patients achieving PASI 75 by week 24 in the ETN&#x02013;ETN and the ETN-ACT groups was numerically more than twice that observed for the ACT group (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>); however, only the pairwise comparison between the ETN-ACT and ACT groups showed statistical significance (<italic>p</italic>&#x02009;=&#x02009;0.0448).<fig id="Fig3"><label>Fig. 3</label><caption><p>Proportion of patients achieving PASI 75 at week 24. <italic>ACT</italic>, acitretin; <italic>ETN</italic>, etanercept; <italic>PASI</italic>, Psoriasis Area Severity Index</p></caption><graphic xlink:href="12895_2016_48_Fig3_HTML" id="MO3"/></fig></p><p>The proportion of patients achieving PASI 75 increased at each visit for all treatment arms (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>). Of the three treatment arms, patients in the ETN&#x02013;ETN group demonstrated the greatest PASI 75 response during the first 18&#x000a0;weeks, after which their response was comparable to that observed for the ETN-ACT group. The PASI 75 responses demonstrated by both of these groups was numerically greater than double that observed for the ACT group. However, statistically significant treatment difference was not shown at any time point.<fig id="Fig4"><label>Fig. 4</label><caption><p>Proportion of patients achieving (<bold>a</bold>) PASI 75, (<bold>b</bold>) PASI 50, and (<bold>c</bold>) PGA clear/almost-clear at each visit. <italic>ACT</italic>, acitretin; <italic>ETN</italic>, etanercept; <italic>PASI</italic>, Psoriasis Area Severity Index; <italic>PGA</italic>, Physician&#x02019;s Global Assessment. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0005</p></caption><graphic xlink:href="12895_2016_48_Fig4_HTML" id="MO4"/></fig></p><p>The proportion of patients achieving PASI 50 increased for all treatment arms (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>). The change from baseline was statistically significant for all treatment arms. A greater proportion of patients in the ETN&#x02013;ETN and ETN-ACT treatment arms achieved PASI 50 at all visits than did patients in the ACT arm.</p><p>The proportion of patients achieving PGA clear/almost-clear increased for all treatment arms (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4c</xref>). Patients in the ETN&#x02013;ETN treatment arm demonstrated the greatest improvements up to week 12, after which improvements were similar to those of patients in the ETN-ACT treatment arm. The proportion of patients achieving PGA clear/almost-clear in the ETN&#x02013;ETN and ETN-ACT arms was more than triple that for the ACT arm.</p><p>The median time to achieve PASI 75 for patients in the ETN&#x02013;ETN arm was 126&#x000a0;days compared with 146&#x000a0;days for patients in the ETN-ACT arm (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The median time to achieve PASI 50 was the same for patients in the ETN&#x02013;ETN and the ETN-ACT arms (56&#x000a0;days) and much shorter than for patients in the ACT arm (126&#x000a0;days). The difference was statistically significant among the three treatment arms (PASI 75: <italic>p</italic>&#x02009;=&#x02009;0.0448 and PASI 50: <italic>p</italic>&#x02009;=&#x02009;0.0033). Additionally, the median time to achieve PGA clear/almost-clear was comparable between the ETN&#x02013;ETN and ETN-ACT treatment arms (167 and 165&#x000a0;days, respectively). The median time to achieve PASI 75 and PGA clear/almost-clear could not be determined for patients in the ACT arm.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Median time to response</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Response</th><th colspan="3">Median time to response, days (95&#x000a0;% CI)</th><th rowspan="2">
<italic>p</italic> value</th></tr><tr><th>ETN 50&#x000a0;mg&#x02013;ETN 25&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;21)</th><th>ETN 25&#x000a0;mg&#x02013;ACT 10&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;19)</th><th>ACT 10&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;18)</th></tr></thead><tbody><tr><td>PASI 75</td><td>126 (56, 146)</td><td>146 (124, NA)</td><td>NA (127, NA)</td><td char="." align="char">0.0448</td></tr><tr><td>PASI 50</td><td>56 (28, 56)</td><td>56 (54, 84)</td><td>126 (56, NA)</td><td char="." align="char">0.0033</td></tr><tr><td>PGA clear/almost-clear</td><td>167 (55, 172)</td><td>165 (59, NA)</td><td>NA (87, NA)</td><td char="." align="char">0.3536</td></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviations</italic>: <italic>ACT</italic> acitretin, <italic>CI</italic> confidence interval, <italic>ETN</italic> etanercept, <italic>NA</italic> not available, <italic>PASI</italic> Psoriasis Area Severity Index, <italic>PGA</italic> Physician&#x02019;s Global Assessment</p></table-wrap-foot></table-wrap></p><p>After 24&#x000a0;weeks of treatment, mean reduction in percent BSA involvement from baseline was greatest in the ETN&#x02013;ETN treatment arm (&#x02212;17.5&#x000a0;%) compared with the ETN-ACT treatment arm (&#x02212;16.9&#x000a0;%) and the ACT treatment arm (&#x02212;10.3&#x000a0;%) at all visits (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). The treatment difference was statistically significant at weeks 4, 8, 12, and 18, whereas the biggest reduction from baseline was at week 24 in all three treatment groups.<fig id="Fig5"><label>Fig. 5</label><caption><p>Change from baseline in percent BSA involvement of psoriasis at each visit. <italic>ANCOVA,</italic> analysis of covariance; <italic>ACT</italic>, acitretin; <italic>BSA</italic>, body surface area; <italic>ETN</italic>, etanercept. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.005 (treatment difference tested by ANCOVA)</p></caption><graphic xlink:href="12895_2016_48_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec9"><title>Safety</title><p>Safety was evaluated on all patients who received at least one dose of study medication. Across the three treatment arms, 38 (64.4&#x000a0;%) patients reported 85 AEs, and 27 (45.8&#x000a0;%) patients reported 46 treatment-related AEs during the study. The overall incidence of AEs was similar in the three treatment arms (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The most common AEs reported across any treatment arm (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) were pruritus (<italic>n</italic>&#x02009;=&#x02009;6, 10.2&#x000a0;%), alopecia (<italic>n</italic>&#x02009;=&#x02009;5, 8.5&#x000a0;%), and dry lips (<italic>n</italic>&#x02009;=&#x02009;5, 8.5&#x000a0;%). One patient in the ACT arm reported a serious AE (severe back pain), which was determined by the investigator not to be related to the study treatment. No life-threatening treatment-emergent AEs occurred during the study nor were there any changes in laboratory tests, vital signs, or physical observations that were considered clinically important (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Summary of treatment-emergent adverse events</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="4">All Causality TEAEs</th><th colspan="4">Treatment-Related AE</th></tr><tr><th>ETN&#x02013;ETN (<italic>n</italic>&#x02009;=&#x02009;21)</th><th>ETN&#x02013;ACT (<italic>n</italic>&#x02009;=&#x02009;20)</th><th>ACT (<italic>n</italic>&#x02009;=&#x02009;18)</th><th>Total (<italic>N</italic>&#x02009;=&#x02009;59)</th><th>ETN&#x02013;ETN (<italic>n</italic>&#x02009;=&#x02009;21)</th><th>ETN&#x02013;ACT (<italic>n</italic>&#x02009;=&#x02009;20)</th><th>ACT (<italic>n</italic>&#x02009;=&#x02009;18)</th><th>Total (<italic>N</italic>&#x02009;=&#x02009;59)</th></tr></thead><tbody><tr><td>Patients with TEAEs, n (%)</td><td>14 (66.7&#x000a0;%)</td><td>14 (70.0&#x000a0;%)</td><td>10 (55.6&#x000a0;%)</td><td>38 (64.4&#x000a0;%)</td><td>9 (42.9&#x000a0;%)</td><td>10 (50.0&#x000a0;%)</td><td>8 (44.4&#x000a0;%)</td><td>27 (45.8&#x000a0;%)</td></tr><tr><td>Total number of TEAEs</td><td>22</td><td>38</td><td>25</td><td>85</td><td>11</td><td>22</td><td>13</td><td>46</td></tr><tr><td>Patients with SAEs, n (%)</td><td>0 (0.0&#x000a0;%)</td><td>0 (0.0&#x000a0;%)</td><td>1 (5.6&#x000a0;%)</td><td>1 (1.7&#x000a0;%)</td><td>0 (0.0&#x000a0;%)</td><td>0 (0.0&#x000a0;%)</td><td>0 (0.0&#x000a0;%)</td><td>0 (0.0&#x000a0;%)</td></tr><tr><td>Total number of SAEs</td><td>0</td><td>0</td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Permanent discontinuation due to AE, n (%)</td><td>1 (4.8&#x000a0;%)</td><td>0</td><td>1 (5.6&#x000a0;%)</td><td>2 (3.4&#x000a0;%)</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviations</italic>: <italic>ACT</italic> acitretin, <italic>AE</italic> adverse event, <italic>ETN</italic> etanercept, <italic>SAE</italic> serious adverse event, <italic>TEAE</italic> treatment-emergent adverse event</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table 4</label><caption><p>Incidence of TEAEs in &#x02265;10&#x000a0;% of patients in any treatment arm</p></caption><table frame="hsides" rules="groups"><thead><tr><th>System organ class</th><th>ETN 50&#x000a0;mg&#x02013;ETN 25&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;21)</th><th>ETN 25&#x000a0;mg&#x02013;ACT 10&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;20)</th><th>ACT 10&#x000a0;mg (<italic>n</italic>&#x02009;=&#x02009;18)</th><th>Total (<italic>N</italic>&#x02009;=&#x02009;59)</th></tr></thead><tbody><tr><td colspan="5">Skin and subcutaneous tissue disorders</td></tr><tr><td>&#x02003;Pruritus</td><td>3 (14.3&#x000a0;%)</td><td>2 (10.0&#x000a0;%)</td><td>1 (5.6&#x000a0;%)</td><td>6 (10.2&#x000a0;%)</td></tr><tr><td>&#x02003;Alopecia</td><td>&#x02013;</td><td>4 (20.0&#x000a0;%)</td><td>1 (5.6&#x000a0;%)</td><td>5 (8.5&#x000a0;%)</td></tr><tr><td>&#x02003;Skin exfoliation</td><td>&#x02013;</td><td>2 (10.0&#x000a0;%)</td><td>1 (5.6&#x000a0;%)</td><td>3 (5.1&#x000a0;%)</td></tr><tr><td colspan="5">Gastrointestinal disorders</td></tr><tr><td>&#x02003;Dry lip</td><td>&#x02013;</td><td>3 (15.0&#x000a0;%)</td><td>2 (11.1&#x000a0;%)</td><td>5 (8.5&#x000a0;%)</td></tr><tr><td>&#x02003;Cheilitis</td><td>&#x02013;</td><td>2 (10.0&#x000a0;%)</td><td>2 (11.1&#x000a0;%)</td><td>4 (6.8&#x000a0;%)</td></tr><tr><td>&#x02003;Chapped lips</td><td>&#x02013;</td><td>1 (5.0&#x000a0;%)</td><td>2 (11.1&#x000a0;%)</td><td>3 (5.1&#x000a0;%)</td></tr><tr><td colspan="5">Investigations</td></tr><tr><td>&#x02003;Alanine aminotransferase increased</td><td>1 (4.8&#x000a0;%)</td><td>2 (10.0&#x000a0;%)</td><td>&#x02013;</td><td>3 (5.1&#x000a0;%)</td></tr><tr><td>&#x02003;Blood bilirubin increased</td><td>&#x02013;</td><td>2 (10.0&#x000a0;%)</td><td>&#x02013;</td><td>2 (3.4&#x000a0;%)</td></tr><tr><td colspan="5">Musculoskeletal and connective tissue disorders</td></tr><tr><td>&#x02003;Myalgia</td><td>&#x02013;</td><td>&#x02013;</td><td>2 (11.1&#x000a0;%)</td><td>2 (3.4&#x000a0;%)</td></tr><tr><td colspan="5">Vascular disorders</td></tr><tr><td>&#x02003;Hypertension</td><td>&#x02013;</td><td>2 (10.0&#x000a0;%)</td><td>&#x02013;</td><td>2 (3.4&#x000a0;%)</td></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviations</italic>: <italic>ACT</italic> acitretin, <italic>ETN</italic> etanercept, <italic>TEAE</italic> treatment-emergent adverse event</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec10"><title>Discussion</title><p>Psoriasis is a chronic autoimmune disease and is often associated with joint inflammation in psoriatic arthritis, a comorbidity that affects between 10 and 30&#x000a0;% of all people with psoriasis [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Severe cases of psoriasis have been shown to affect health-related QoL to an extent similar to the effects of other chronic diseases such as depression, hypertension, congestive heart failure, or type 2 diabetes [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p>In multiple trials, etanercept has been shown to be effective in improving the disease severity of psoriasis and patient QoL [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. However, treatment with high doses of etanercept can be expensive [<xref ref-type="bibr" rid="CR28">28</xref>]. In this context, even though acitretin monotherapy is often only moderately effective [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>], acitretin is widely used to treat psoriasis and is considered a standard of care in Korea. Furthermore, acitretin has been reported to have malignancy chemoprevention characteristics [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Since acitretin is not an immunosuppressive agent and may act synergistically with biologic agents (e.g., etanercept), with a low risk of toxicity, a combination of etanercept and acitretin could be a viable treatment option for patients with psoriasis while keeping treatment affordable and potentially having additional beneficial effects. The results of a pilot study [<xref ref-type="bibr" rid="CR25">25</xref>], a case series [<xref ref-type="bibr" rid="CR30">30</xref>], and a posthoc review of clinical treatment practice [<xref ref-type="bibr" rid="CR24">24</xref>] have suggested that the combination of etanercept and acitretin is effective and safe for the treatment of psoriasis. However, the efficacy and safety of this combination to treat Korean patients with psoriasis have not been determined until now.</p><p>The data presented here demonstrate that the combination of etanercept 25&#x000a0;mg BIW&#x02009;+&#x02009;acitretin 10&#x000a0;mg BID appears to be as effective for the treatment of psoriasis in Korean patients as etanercept 50&#x000a0;mg BIW for 12&#x000a0;weeks followed by etanercept 25&#x000a0;mg BIW. Furthermore, based on the numerical proportion of patients achieving efficacy endpoints (i.e., PASI 75, PASI 50, PGA clear/almost-clear, and reduction in disease-related BSA), and time to achieve these efficacy endpoints (i.e., time to achieve PASI 75, PASI 50, and PGA clear/almost-clear), both of these treatments appear to be more effective than acitretin 10&#x000a0;mg BID alone. In particular, the PASI 75 response rate at week 24 for the combined treatment arm (57.9&#x000a0;%) and the etanercept 50&#x000a0;mg&#x02013;etanercept 25&#x000a0;mg arm (52.4&#x000a0;%) was numerically more than twice the rate of the acitretin 10&#x000a0;mg arm (22.2&#x000a0;%), although the differences were not statistically significant. However, unadjusted pairwise comparison showed a significant difference between the combined treatment group and acitretin 10&#x000a0;mg group (<italic>p</italic>&#x02009;=&#x02009;0.0448). Furthermore, the proportion of patients achieving PGA clear/almost-clear in the ETN&#x02013;ETN and ETN-ACT arms was more than triple that for the ACT arm. It is possible that due to the small number of patients, statistical significance was not achieved between the ETN&#x02013;ETN and ETN-ACT arms and the ACT arm. Our results are consistent with an earlier Italian, randomized, controlled, pilot trial that showed PASI 75 response at week 24 was achieved by 45&#x000a0;% of the patients in the etanercept 25&#x000a0;mg BIW group, 44&#x000a0;% of the patients treated with etanercept 25&#x000a0;mg&#x02009;+&#x02009;acitretin, and 30&#x000a0;% of the patients in the acitretin 0.4&#x000a0;mg-kg<sup>&#x02212;1</sup> daily group. However, etanercept 25&#x000a0;mg BIW is not commonly effective in treating plaque psoriasis. Consequently, in our study, we treated patients at a higher initial dose of etanercept (50&#x000a0;mg BIW) and adjusted the dose downward to 25&#x000a0;mg BIW as the patients improved &#x02013; a treatment regimen that we believe better reflects the real-world conditions.</p><p>These data demonstrate that the combination of etanercept with acitretin is just as effective as etanercept alone at week 24. However, patients treated with etanercept alone achieved the efficacy outcome endpoints faster than did patients receiving the combination. Treatment with etanercept alone may be preferred by patients wanting a more rapid resolution of their disease whereas treatment with the combination of these two drugs may be preferable for others without sacrificing efficacy or safety. The treating physician will need to consider these options in consultation with the patient to determine the optimum treatment regimen.</p><p>All treatments appeared to be safe and well tolerated by the patients. The incidence and severity of AEs appeared to be similar across all treatment arms. No life-threatening AEs were reported and no patient-reported SAEs that were related to study treatment. For patients with skin diseases, these results are important in terms of satisfaction with treatment and improvement of signs and symptoms of the disease, and could potentially affect their QoL.</p></sec><sec id="Sec11"><title>Conclusions</title><p>In this study, the treatment of psoriasis with the combination therapy of etanercept and acitretin substantially reduced the severity of disease in Korean patients over a period of 24&#x000a0;weeks. These results suggest that etanercept could be added to acitretin to treat Korean patients with psoriasis, especially when the disease is resistant or responding inadequately to topical treatment or phototherapy. Combination therapy of etanercept and acitretin, and etanercept alone, are both effective and well tolerated; however, the choice of treatment may depend on finding a balance between the costs of the treatment versus the rapidity with which patients desire to experience the benefits of the treatment.</p></sec><sec id="Sec12"><title>Abbreviations</title><p>ACT, acitretin; AE, adverse event; ANCOVA, analysis of covariance; ANOVA, analysis of variance; BID, twice daily; BIW, twice weekly; BSA, body surface area; CI, confidence interval; ETN, etanercept; mITT, modified intent-to-treat population; NA, not available; PASI, Psoriasis Area and Severity Index; PGA, Physician&#x02019;s Global Assessment; PP, per-protocol population; PUVA, psoralen plus ultraviolet A radiation therapy; QoL, quality of life; SAE, serious adverse event; SD, standard deviation; TEAE, treatment-emergent adverse event; TNF&#x003b1;, tumor necrosis factor alpha</p></sec></body><back><app-group><app id="App1"><sec id="Sec13"><title>Appendix</title><p><table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td>Site ID</td><td>Institution</td><td>PI</td><td>IRB No.</td></tr><tr><td>1002</td><td>Hallym University Medical Center</td><td>Kwang-Joong Kim</td><td>2010-S003</td></tr><tr><td>1003</td><td>The Catholic University of Korea Seoul St. Mary&#x02019;s Hospital</td><td>Tae-Yoon Kim</td><td>KC09MSMV0185</td></tr><tr><td>1004</td><td>Samsung Medical Center</td><td>Joo-Heung Lee</td><td>2009-08-101</td></tr><tr><td>1005</td><td>Asian Medical Center</td><td>JeeHo Choi</td><td>2009-0645</td></tr><tr><td>1006</td><td>Bucheon St. Mary&#x02019;s Hospital</td><td>ChulJong Park</td><td>HC09BSMV0091</td></tr><tr><td>1007</td><td>Konkuk University Hospital</td><td>YongBeom Choe</td><td>KUH1120010</td></tr><tr><td>1008</td><td>Korea University Medical Center, Guro Hospital</td><td>HaeJun Song</td><td>GR09163-001</td></tr><tr><td>1009</td><td>Kyung Hee University Medical Center</td><td>NackIn Kim</td><td>KMC IRB 0922-05</td></tr><tr><td>1010</td><td>Seoul National University Hospital</td><td>Jai-Il Yoon</td><td>H-0911-041-301</td></tr><tr><td>1011</td><td>Chungnam National University Hospital</td><td>JeungHoon Lee</td><td>0912-128</td></tr></tbody></table></table-wrap></p></sec></app></app-group><ack><title>Acknowledgements</title><p>Medical writing support was provided by Mukund Nori, PhD, MBA, CMPP, of Engage Scientific Solutions and was funded by Pfizer.</p><sec id="FPar1"><title>Funding</title><p>This study was funded by Pfizer Pharmaceuticals Korea Limited; etanercept is a product of Pfizer.</p></sec><sec id="FPar2"><title>Availability of data and material</title><p>The dataset supporting the conclusions of this article are included within the article and available at <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/results/NCT00936065">https://clinicaltrials.gov/ct2/show/results/NCT00936065</ext-link>.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>All authors participated in study design, data collection, data interpretation, development, review, and final approval of the manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>Hyun-Jeong Yoo is an employee of Pfizer Pharmaceuticals Korea Limited; etanercept is a product of Pfizer. All other authors report no competing interests.</p></sec><sec id="FPar5"><title>Ethics approval and consent to participate</title><p>This study was reviewed and approved by local Institutional Review Boards (Appendix) and was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with Good Clinical Practice Guidelines. All patients provided signed informed consent.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parisi</surname><given-names>R</given-names></name><name><surname>Symmons</surname><given-names>DPM</given-names></name><name><surname>Griffiths</surname><given-names>CEM</given-names></name><name><surname>Ashcroft</surname><given-names>DM</given-names></name></person-group><article-title>Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence</article-title><source>J Invest Dermatol</source><year>2013</year><volume>133</volume><issue>2</issue><fpage>377</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1038/jid.2012.339</pub-id><pub-id pub-id-type="pmid">23014338</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Science of Psoriasis: Statistics [<ext-link ext-link-type="uri" xlink:href="https://www.psoriasis.org/sites/default/files/psoriasis_fact_sheet.pdf">https://www.psoriasis.org/sites/default/files/psoriasis_fact_sheet.pdf</ext-link>].</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Facts about psoriasis [<ext-link ext-link-type="uri" xlink:href="http://www.worldpsoriasisday.com/web/page.aspx?refid=130">http://www.worldpsoriasisday.com/web/page.aspx?refid=130</ext-link>].</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>CE</given-names></name><name><surname>Barker</surname><given-names>JN</given-names></name></person-group><article-title>Pathogenesis and clinical features of psoriasis</article-title><source>Lancet</source><year>2007</year><volume>370</volume><issue>9583</issue><fpage>263</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)61128-3</pub-id><pub-id pub-id-type="pmid">17658397</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>G</given-names></name><name><surname>Waxman</surname><given-names>R</given-names></name><name><surname>Helliwell</surname><given-names>PS</given-names></name></person-group><article-title>The prevalence of psoriatic arthritis in people with psoriasis</article-title><source>Arthritis Rheum</source><year>2009</year><volume>61</volume><issue>10</issue><fpage>1373</fpage><lpage>1378</lpage><pub-id pub-id-type="doi">10.1002/art.24608</pub-id><pub-id pub-id-type="pmid">19790120</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qureshi</surname><given-names>AA</given-names></name><name><surname>Choi</surname><given-names>HK</given-names></name><name><surname>Setty</surname><given-names>AR</given-names></name><name><surname>Curhan</surname><given-names>GC</given-names></name></person-group><article-title>Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses</article-title><source>Arch Dermatol</source><year>2009</year><volume>145</volume><issue>4</issue><fpage>379</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1001/archdermatol.2009.48</pub-id><pub-id pub-id-type="pmid">19380659</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>N</given-names></name><name><surname>Quaranta</surname><given-names>M</given-names></name><name><surname>Prescott</surname><given-names>NJ</given-names></name><name><surname>Allen</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Burden</surname><given-names>AD</given-names></name><name><surname>Worthington</surname><given-names>J</given-names></name><name><surname>Griffiths</surname><given-names>CE</given-names></name><name><surname>Mathew</surname><given-names>CG</given-names></name><name><surname>Barker</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease</article-title><source>J Med Genet</source><year>2008</year><volume>45</volume><issue>2</issue><fpage>114</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1136/jmg.2007.053595</pub-id><pub-id pub-id-type="pmid">17993580</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlehoff</surname><given-names>O</given-names></name></person-group><article-title>Psoriasis and Cardiovascular Disease: epidemiological studies</article-title><source>Dan Med Bull</source><year>2011</year><volume>58</volume><issue>11</issue><fpage>B4347</fpage><pub-id pub-id-type="pmid">22047936</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurd</surname><given-names>SK</given-names></name><name><surname>Troxel</surname><given-names>AB</given-names></name><name><surname>Crits-Christoph</surname><given-names>P</given-names></name><name><surname>Gelfand</surname><given-names>JM</given-names></name></person-group><article-title>The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study</article-title><source>Arch Dermatol</source><year>2010</year><volume>146</volume><issue>8</issue><fpage>891</fpage><lpage>895</lpage><pub-id pub-id-type="pmid">20713823</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubertret</surname><given-names>L</given-names></name><name><surname>Mrowietz</surname><given-names>U</given-names></name><name><surname>Ranki</surname><given-names>A</given-names></name><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>Chimenti</surname><given-names>S</given-names></name><name><surname>Lotti</surname><given-names>T</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>G</given-names></name></person-group><article-title>European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey</article-title><source>Br J Dermatol</source><year>2006</year><volume>155</volume><issue>4</issue><fpage>729</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2006.07405.x</pub-id><pub-id pub-id-type="pmid">16965422</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menter</surname><given-names>A</given-names></name><name><surname>Gottlieb</surname><given-names>A</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name><name><surname>Van Voorhees</surname><given-names>AS</given-names></name><name><surname>Leonardi</surname><given-names>CL</given-names></name><name><surname>Gordon</surname><given-names>KB</given-names></name><name><surname>Lebwohl</surname><given-names>M</given-names></name><name><surname>Koo</surname><given-names>JY</given-names></name><name><surname>Elmets</surname><given-names>CA</given-names></name><name><surname>Korman</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics</article-title><source>J Am Acad Dermatol</source><year>2008</year><volume>58</volume><issue>5</issue><fpage>826</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2008.02.039</pub-id><pub-id pub-id-type="pmid">18423260</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb</surname><given-names>A</given-names></name><name><surname>Korman</surname><given-names>NJ</given-names></name><name><surname>Gordon</surname><given-names>KB</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name><name><surname>Lebwohl</surname><given-names>M</given-names></name><name><surname>Koo</surname><given-names>JY</given-names></name><name><surname>Van Voorhees</surname><given-names>AS</given-names></name><name><surname>Elmets</surname><given-names>CA</given-names></name><name><surname>Leonardi</surname><given-names>CL</given-names></name><name><surname>Beutner</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics</article-title><source>J Am Acad Dermatol</source><year>2008</year><volume>58</volume><issue>5</issue><fpage>851</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2008.02.040</pub-id><pub-id pub-id-type="pmid">18423261</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menter</surname><given-names>A</given-names></name><name><surname>Korman</surname><given-names>NJ</given-names></name><name><surname>Elmets</surname><given-names>CA</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name><name><surname>Gelfand</surname><given-names>JM</given-names></name><name><surname>Gordon</surname><given-names>KB</given-names></name><name><surname>Gottlieb</surname><given-names>A</given-names></name><name><surname>Koo</surname><given-names>JY</given-names></name><name><surname>Lebwohl</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>HW</given-names></name><etal/></person-group><article-title>Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies</article-title><source>J Am Acad Dermatol</source><year>2009</year><volume>60</volume><issue>4</issue><fpage>643</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2008.12.032</pub-id><pub-id pub-id-type="pmid">19217694</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menter</surname><given-names>A</given-names></name><name><surname>Korman</surname><given-names>NJ</given-names></name><name><surname>Elmets</surname><given-names>CA</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name><name><surname>Gelfand</surname><given-names>JM</given-names></name><name><surname>Gordon</surname><given-names>KB</given-names></name><name><surname>Gottlieb</surname><given-names>AB</given-names></name><name><surname>Koo</surname><given-names>JY</given-names></name><name><surname>Lebwohl</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>HW</given-names></name><etal/></person-group><article-title>Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents</article-title><source>J Am Acad Dermatol</source><year>2009</year><volume>61</volume><issue>3</issue><fpage>451</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2009.03.027</pub-id><pub-id pub-id-type="pmid">19493586</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menter</surname><given-names>A</given-names></name><name><surname>Korman</surname><given-names>NJ</given-names></name><name><surname>Elmets</surname><given-names>CA</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name><name><surname>Gelfand</surname><given-names>JM</given-names></name><name><surname>Gordon</surname><given-names>KB</given-names></name><name><surname>Gottlieb</surname><given-names>A</given-names></name><name><surname>Koo</surname><given-names>JY</given-names></name><name><surname>Lebwohl</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>HW</given-names></name><etal/></person-group><article-title>Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy</article-title><source>J Am Acad Dermatol</source><year>2010</year><volume>62</volume><issue>1</issue><fpage>114</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2009.08.026</pub-id><pub-id pub-id-type="pmid">19811850</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menter</surname><given-names>A</given-names></name><name><surname>Korman</surname><given-names>NJ</given-names></name><name><surname>Elmets</surname><given-names>CA</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name><name><surname>Gelfand</surname><given-names>JM</given-names></name><name><surname>Gordon</surname><given-names>KB</given-names></name><name><surname>Gottlieb</surname><given-names>A</given-names></name><name><surname>Koo</surname><given-names>JY</given-names></name><name><surname>Lebwohl</surname><given-names>M</given-names></name><name><surname>Leonardi</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions</article-title><source>J Am Acad Dermatol</source><year>2011</year><volume>65</volume><issue>1</issue><fpage>137</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2010.11.055</pub-id><pub-id pub-id-type="pmid">21306785</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papp</surname><given-names>KA</given-names></name><name><surname>Tyring</surname><given-names>S</given-names></name><name><surname>Lahfa</surname><given-names>M</given-names></name><name><surname>Prinz</surname><given-names>J</given-names></name><name><surname>Griffiths</surname><given-names>CE</given-names></name><name><surname>Nakanishi</surname><given-names>AM</given-names></name><name><surname>Zitnik</surname><given-names>R</given-names></name><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>Melvin</surname><given-names>L</given-names></name></person-group><article-title>A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction</article-title><source>Br J Dermatol</source><year>2005</year><volume>152</volume><issue>6</issue><fpage>1304</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2005.06688.x</pub-id><pub-id pub-id-type="pmid">15948997</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>Segaert</surname><given-names>S</given-names></name><name><surname>Lahfa</surname><given-names>M</given-names></name><name><surname>Luger</surname><given-names>TA</given-names></name><name><surname>Karolyi</surname><given-names>Z</given-names></name><name><surname>Kaszuba</surname><given-names>A</given-names></name><name><surname>Leigheb</surname><given-names>G</given-names></name><name><surname>Camacho</surname><given-names>FM</given-names></name><name><surname>Forsea</surname><given-names>D</given-names></name><name><surname>Zang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Once weekly administration of etanercept 50&#x000a0;mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension</article-title><source>Br J Dermatol</source><year>2008</year><volume>159</volume><issue>5</issue><fpage>1177</fpage><lpage>1185</lpage><pub-id pub-id-type="pmid">18673365</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strohal</surname><given-names>R</given-names></name><name><surname>Puig</surname><given-names>L</given-names></name><name><surname>Chouela</surname><given-names>E</given-names></name><name><surname>Tsai</surname><given-names>TF</given-names></name><name><surname>Melin</surname><given-names>J</given-names></name><name><surname>Freundlich</surname><given-names>B</given-names></name><name><surname>Molta</surname><given-names>CT</given-names></name><name><surname>Fuiman</surname><given-names>J</given-names></name><name><surname>Pedersen</surname><given-names>R</given-names></name><name><surname>Robertson</surname><given-names>D</given-names></name></person-group><article-title>The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)</article-title><source>J Dermatolog Treat</source><year>2013</year><volume>24</volume><issue>3</issue><fpage>169</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.3109/09546634.2012.658015</pub-id><pub-id pub-id-type="pmid">22251226</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thaci</surname><given-names>D</given-names></name><name><surname>Galimberti</surname><given-names>R</given-names></name><name><surname>Amaya-Guerra</surname><given-names>M</given-names></name><name><surname>Rosenbach</surname><given-names>T</given-names></name><name><surname>Robertson</surname><given-names>D</given-names></name><name><surname>Pedersen</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Kuligowski</surname><given-names>M</given-names></name><name><surname>Boggs</surname><given-names>R</given-names></name></person-group><article-title>Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial</article-title><source>J Eur Acad Dermatol Venereol</source><year>2013</year><volume>28</volume><issue>7</issue><fpage>900</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1111/jdv.12207</pub-id><pub-id pub-id-type="pmid">23848989</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>LK</given-names></name><name><surname>Gaar</surname><given-names>LR</given-names></name><name><surname>Yentzer</surname><given-names>BA</given-names></name><name><surname>O&#x02019;Neill</surname><given-names>JL</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name></person-group><article-title>Acitretin in dermatology: a review</article-title><source>J Drugs Dermatol</source><year>2011</year><volume>10</volume><issue>7</issue><fpage>772</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">21720660</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claes</surname><given-names>C</given-names></name><name><surname>Kulp</surname><given-names>W</given-names></name><name><surname>Greiner</surname><given-names>W</given-names></name><name><surname>von der Schulenburg</surname><given-names>JM</given-names></name><name><surname>Werfel</surname><given-names>T</given-names></name></person-group><article-title>Therapy of moderate and severe psoriasis</article-title><source>GMS Health Technol Assess</source><year>2006</year><volume>2</volume><fpage>Doc07</fpage><pub-id pub-id-type="pmid">21289958</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monfrecola</surname><given-names>G</given-names></name><name><surname>Baldo</surname><given-names>A</given-names></name></person-group><article-title>Retinoids and phototherapy for psoriasis</article-title><source>J Rheumatol Suppl</source><year>2009</year><volume>83</volume><fpage>71</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.3899/jrheum.090231</pub-id><pub-id pub-id-type="pmid">19661548</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>EC</given-names></name><name><surname>Riddle</surname><given-names>C</given-names></name><name><surname>Menter</surname><given-names>MA</given-names></name><name><surname>Lebwohl</surname><given-names>M</given-names></name></person-group><article-title>Combining systemic retinoids with biologic agents for moderate to severe psoriasis</article-title><source>Int J Dermatol</source><year>2008</year><volume>47</volume><issue>5</issue><fpage>514</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1111/j.1365-4632.2008.03470.x</pub-id><pub-id pub-id-type="pmid">18412874</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gisondi</surname><given-names>P</given-names></name><name><surname>Del Giglio</surname><given-names>M</given-names></name><name><surname>Cotena</surname><given-names>C</given-names></name><name><surname>Girolomoni</surname><given-names>G</given-names></name></person-group><article-title>Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial</article-title><source>Br J Dermatol</source><year>2008</year><volume>158</volume><issue>6</issue><fpage>1345</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2008.08564.x</pub-id><pub-id pub-id-type="pmid">18410408</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Committee for Medicinal Products for Human Use (CHMP)</collab></person-group><source>Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis</source><year>2004</year><publisher-loc>London</publisher-loc><publisher-name>European Medicines Agency</publisher-name></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampogna</surname><given-names>F</given-names></name><name><surname>Chren</surname><given-names>MM</given-names></name><name><surname>Melchi</surname><given-names>CF</given-names></name><name><surname>Pasquini</surname><given-names>P</given-names></name><name><surname>Tabolli</surname><given-names>S</given-names></name><name><surname>Abeni</surname><given-names>D</given-names></name></person-group><article-title>Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis</article-title><source>Br J Dermatol</source><year>2006</year><volume>154</volume><issue>2</issue><fpage>325</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2005.06909.x</pub-id><pub-id pub-id-type="pmid">16433804</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Souza</surname><given-names>LS</given-names></name><name><surname>Payette</surname><given-names>MJ</given-names></name></person-group><article-title>Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis</article-title><source>J Am Acad Dermatol</source><year>2015</year><volume>72</volume><issue>4</issue><fpage>589</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2014.11.028</pub-id><pub-id pub-id-type="pmid">25631851</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettoli</surname><given-names>V</given-names></name><name><surname>Zauli</surname><given-names>S</given-names></name><name><surname>Virgili</surname><given-names>A</given-names></name></person-group><article-title>Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how</article-title><source>J Dermatolog Treat</source><year>2013</year><volume>24</volume><issue>3</issue><fpage>235</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.3109/09546634.2012.746634</pub-id><pub-id pub-id-type="pmid">23148804</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conley</surname><given-names>J</given-names></name><name><surname>Nanton</surname><given-names>J</given-names></name><name><surname>Dhawan</surname><given-names>S</given-names></name><name><surname>Pearce</surname><given-names>DJ</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name></person-group><article-title>Novel combination regimens: biologics and acitretin for the treatment of psoriasis-- a case series</article-title><source>J Dermatolog Treat</source><year>2006</year><volume>17</volume><issue>2</issue><fpage>86</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1080/09546630500482928</pub-id><pub-id pub-id-type="pmid">16766332</pub-id></element-citation></ref></ref-list></back></article>